Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD) and OS Therapies Incorporated (OSTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mind Medicine (MNMD – Research Report) and OS Therapies Incorporated (OSTX – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Mind Medicine (MNMD)

LifeSci Capital analyst Francois Brisebois initiated coverage with a Buy rating on Mind Medicine on October 14 and set a price target of $32.00. The company’s shares closed last Thursday at $11.91, close to its 52-week high of $12.22.

According to TipRanks.com, Brisebois has 0 stars on 0-5 stars ranking scale with an average return of -4.7% and a 35.4% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Centessa Pharmaceuticals, and Aquestive Therapeutics. ;'>

Mind Medicine has an analyst consensus of Strong Buy, with a price target consensus of $27.10, implying an 112.4% upside from current levels. In a report issued on October 13, Needham also initiated coverage with a Buy rating on the stock with a $28.00 price target.

See today’s best-performing stocks on TipRanks >>

OS Therapies Incorporated (OSTX)

In a report issued on October 14, Chad Messer from Lake Street maintained a Buy rating on OS Therapies Incorporated, with a price target of $18.00. The company’s shares closed last Thursday at $1.85, close to its 52-week low of $1.41.

According to TipRanks.com, Messer is a 1-star analyst with an average return of -0.4% and a 39.5% success rate. Messer covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Coya Therapeutics, Inc., and Bolt Biotherapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OS Therapies Incorporated with a $12.00 average price target, which is a 518.6% upside from current levels. In a report issued on September 30, Maxim Group also maintained a Buy rating on the stock with a $6.00 price target.

Read More on MNMD:

Disclaimer & DisclosureReport an Issue

• Psychedelic: Needham initiates coverage of atai, GH Research, MindMed
• MindMed Issues Inducement Grant to New Employee
• Mind Medicine initiated with an Outperform at LifeSci Capital
• 3 Best Stocks to Buy Now, 10/13/2025, According to Top Analysts
• Mind Medicine’s MM120: Promising Phase 3 Trials and Strategic Growth Potential